skip to Main Content
Back To Top
- A 31-biomarker blood test could distinguish patients with early-stage pancreatic ductal adenocarcinoma (PDAC) from healthy persons with a high degree of accuracy.
- Individually weak serum biomarkers, such as CEA and CA 19-9, were combined into a robust screening assay.
Why This Matters
- About 65% of patients with PDAC present late with unresectable disease.
- An accurate, cost-effective blood test to catch early, asymptomatic disease could substantially increase the number of patients eligible for curative surgery. Read more . . . .